Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.54 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.53 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.46 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.46 |
| ▸ | PDXK | O00764 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8835556 | 0.87 | KDM4E (0.59) | KDM4ELMNAALDH1A1HPGDMEN1 | |
| SCHEMBL17224491 | 0.84 | KDM4E (0.56) | KDM4ELMNAALDH1A1HPGDMEN1 | |
| SCHEMBL6045299 | 0.83 | KDM4E (0.54) | KDM4ELMNAALDH1A1HPGDMEN1 | |
| SCHEMBL14687825 | 0.81 | KDM4E (0.53) | KDM4ELMNAALDH1A1HPGDMEN1 | |
| SCHEMBL4576456 | 0.79 | ESR1 (0.52) | KDM4ELMNAALDH1A1HPGDMEN1 | |
| SCHEMBL8265770 | 0.76 | KDM4E (0.62) | KDM4ELMNAALDH1A1HPGDMEN1 | |
| SCHEMBL3220371 | 0.75 | LMNA (0.43) | KDM4ELMNAALDH1A1HPGDMEN1 | |
| SCHEMBL11011837 | 0.75 | KDM4E (0.57) | KDM4ELMNAALDH1A1HPGDMEN1 | |
| SCHEMBL26649434 | 0.73 | KDM4E (0.59) | KDM4ELMNAALDH1A1HPGDMEN1 | |
| SCHEMBL2692050 | 0.72 | P2RX2 (0.56) | KDM4ELMNAALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112822995-B | Topical compositions | 帝斯曼知识产权资产管理有限公司 | 2023-06-02 | — | — | CN | claimed |
| WO-2019148849-A1 | TERNARY HERBICIDAL COMPOSITION AND USE THEREOF | 青岛清原化合物有限公司 | 2019-08-08 | — | — | WO | claimed |
| CN-103534345-A | Cell culture media for UVC exposure and methods relating thereto | AMGEN INC | 2014-01-22 | — | — | CN | disclosed |
| US-8481283-B2 | Pressure-assisted molecular recovery (PAMR) of biomolecules, pressure-assisted antigen retrieval (PAAR), and pressure-assisted tissue histology (PATH) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2013-07-09 | — | — | US | disclosed |
| US-20130011854-A1 | PRESSURE-ASSISTED MOLECULAR RECOVERY (PAMR) OF BIOMOLECULES, PRESSURE-ASSISTED ANTIGEN RETRIEVAL (PAAR), AND PRESSURE-ASSISTED TISSUE HISTOLOGY (PATH) | The United States Government as represented by the Dept. of Veterans Affairs | 2013-01-10 | — | — | US | disclosed |
| US-8288122-B2 | Pressure-assisted molecular recovery (PAMR) of biomolecules, pressure-assisted antigen retrieval (PAAR), and pressure-assisted tissue histology (PATH) | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2370803-A2 | PRESSURE-ASSISTED MOLECULAR RECOVERY (PAMR) OF BIOMOLECULES, PRESSURE-ASSISTED ANTIGEN RETRIEVAL (PAAR), AND PRESSURE-ASSISTED TISSUE HISTOLOGY (PATH) | The United States Government As Represented By The Department Of Veterans Affairs (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010065775-A2 | PRESSURE-ASSISTED MOLECULAR RECOVERY (PAMR) OF BIOMOLECULES, PRESSURE-ASSISTED ANTIGEN RETRIEVAL (PAAR), AND PRESSURE-ASSISTED TISSUE HISTOLOGY (PATH) | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100136613-A1 | PRESSURE-ASSISTED MOLECULAR RECOVERY (PAMR) OF BIOMOLECULES, PRESSURE-ASSISTED ANTIGEN RETRIEVAL (PAAR), AND PRESSURE-ASSISTED TISSUE HISTOLOGY (PATH) | The Government of the United States of America as represented by the Department of Veterans Affairs | 2010-06-03 | — | — | US | disclosed |
| US-20070155801-A1 | Advanced glycation end-product intermediaries and post-amadori inhibition | UNIVERSITY OF KANSAS MEDICAL CENTER | 2007-07-05 | — | — | US | disclosed |
| US-7030146-B2 | Methods for treating diabetic neuropathy | UNIVERSITY OF SOUTH CAROLINA (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1032562-A2 | ADVANCED GLYCATION END-PRODUCT INTERMEDIARIES AND POST-AMADORI INHIBITION | University of Kansas Medical Center (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-2000023063-A2 | METHODS FOR INHIBITING DIABETIC COMPLICATIONS | UNIVERSITY OF SOUTH CAROLINA (US) | 2000-04-27 | — | — | WO | disclosed |
| WO-2000021516-A2 | METHODS FOR INHIBITING DIABETIC COMPLICATIONS | KANSAS UNIVERSITY MEDICAL CENTER RESEARCH INSTITUTE, INC. (US) | 2000-04-20 | — | — | WO | disclosed |
| WO-2000022094-A2 | METHODS FOR INHIBITING OXIDATIVE MODIFICATION OF PROTEINS | KANSAS UNIVERSITY MEDICAL CENTER (US) | 2000-04-20 | — | — | WO | disclosed |
| US-5985857-A | GENERATING STABLE PROTEIN-SUGAR POST-AMADORI ADVANCED GLYCATION END-PRODUCT (AGE) INTERMEDIATES COMPRISING INCUBATING PROTEIN WITH PENTOSE SUGAR | KANSAS UNIVERSITY MEDICAL CENTER (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1999025690-A2 | ADVANCED GLYCATION END-PRODUCT INTERMEDIARIES AND POST-AMADORI INHIBITION | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 1999-05-27 | — | — | WO | disclosed |
| EP-0871443-A1 | ADVANCED GLYCATION END-PRODUCT INTERMEDIARIES AND POST-AMADORI INHIBITION | THE UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997009981-A1 | ADVANCED GLYCATION END-PRODUCT INTERMEDIARIES AND POST-AMADORI INHIBITION | UNIVERSITY OF KANSAS MEDICAL CENTER (US) | 1997-03-20 | — | — | WO | disclosed |
| WO-1993014751-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AS ACTIVE PRINCIPLE ASSOCIATIONS OF VANADIUM AND/OR NIOBIUM WITH PYROCATECHOL DERIVATIVES | I.R.2.M. (FR) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155801-A1 | Advanced glycation end-product intermediaries and post-amadori inhibition | AGER, DPP4, OGA | KDM4E 1533/4885LMNA 484/4885ALDH1A1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.